相似文献
1
Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.
Free Radic Biol Med. 2013 Sep;62:102-110. doi: 10.1016/j.freeradbiomed.2013.04.017. Epub 2013 Apr 18.
2
Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.
Free Radic Biol Med. 2012 Oct 1;53(7):1478-88. doi: 10.1016/j.freeradbiomed.2012.06.008. Epub 2012 Jun 16.
3
PGC-1α, mitochondrial dysfunction, and Huntington's disease.
Free Radic Biol Med. 2013 Sep;62:37-46. doi: 10.1016/j.freeradbiomed.2013.04.016. Epub 2013 Apr 19.
4
Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex.
Hum Mol Genet. 2017 Jan 15;26(2):395-406. doi: 10.1093/hmg/ddw395.
5
Stoichiometry of base excision repair proteins correlates with increased somatic CAG instability in striatum over cerebellum in Huntington's disease transgenic mice.
PLoS Genet. 2009 Dec;5(12):e1000749. doi: 10.1371/journal.pgen.1000749. Epub 2009 Dec 4.
6
Mitochondrial diseases of the brain.
Free Radic Biol Med. 2013 Oct;63:1-29. doi: 10.1016/j.freeradbiomed.2013.03.018. Epub 2013 Apr 6.
7
Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.
Chang Gung Med J. 2011 Mar-Apr;34(2):135-52.
8
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.
Hum Mol Genet. 2010 Oct 15;19(20):3919-35. doi: 10.1093/hmg/ddq306. Epub 2010 Jul 21.
9
PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.
Prog Neurobiol. 2012 May;97(2):142-51. doi: 10.1016/j.pneurobio.2011.10.004. Epub 2011 Nov 9.
10
Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases.
Neuroscience. 2007 Apr 14;145(4):1233-48. doi: 10.1016/j.neuroscience.2006.10.056. Epub 2007 Feb 14.
引用本文的文献
1
Huntingtin preserves mitochondrial genome integrity in neurons, which is impaired in Huntington's disease.
bioRxiv. 2025 Jul 24:2025.07.24.666629. doi: 10.1101/2025.07.24.666629.
2
Detecting mtDNA Effects with an Extended Pedigree Model: An Analysis of Statistical Power and Estimation Bias.
Behav Genet. 2025 Jul 16. doi: 10.1007/s10519-025-10225-1.
3
Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy.
Front Pharmacol. 2025 Mar 19;15:1505867. doi: 10.3389/fphar.2024.1505867. eCollection 2024.
4
DNA damage response regulator ATR licenses PINK1-mediated mitophagy.
Nucleic Acids Res. 2025 Feb 27;53(5). doi: 10.1093/nar/gkaf178.
5
F2,6BP restores mitochondrial genome integrity in Huntington's Disease.
bioRxiv. 2025 Jun 30:2024.11.04.621834. doi: 10.1101/2024.11.04.621834.
6
mA modification of mutant huntingtin RNA promotes the biogenesis of pathogenic huntingtin transcripts.
EMBO Rep. 2024 Nov;25(11):5026-5052. doi: 10.1038/s44319-024-00283-7. Epub 2024 Oct 11.
7
The Biological Activity of on Neurodegenerative Diseases: The Interplay between Different Active Compounds and the Pathological Hallmarks.
Molecules. 2024 May 26;29(11):2516. doi: 10.3390/molecules29112516.
8
Research progress on ferroptosis in the pathogenesis and treatment of neurodegenerative diseases.
Front Cell Neurosci. 2024 Mar 7;18:1359453. doi: 10.3389/fncel.2024.1359453. eCollection 2024.
9
Using Redox Proteomics to Gain New Insights into Neurodegenerative Disease and Protein Modification.
Antioxidants (Basel). 2024 Jan 20;13(1):127. doi: 10.3390/antiox13010127.
10
Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases.
Arch Toxicol. 2024 Mar;98(3):579-615. doi: 10.1007/s00204-023-03660-8. Epub 2024 Jan 24.
本文引用的文献
1
Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.
Cell Rep. 2012 Nov 29;2(5):1137-42. doi: 10.1016/j.celrep.2012.10.001. Epub 2012 Nov 1.
2
Neil1 is a genetic modifier of somatic and germline CAG trinucleotide repeat instability in R6/1 mice.
Hum Mol Genet. 2012 Nov 15;21(22):4939-47. doi: 10.1093/hmg/dds337. Epub 2012 Aug 21.
3
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
Sci Transl Med. 2012 Jul 11;4(142):142ra97. doi: 10.1126/scitranslmed.3003799.
4
Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.
Free Radic Biol Med. 2012 Oct 1;53(7):1478-88. doi: 10.1016/j.freeradbiomed.2012.06.008. Epub 2012 Jun 16.
5
trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease.
J Biol Chem. 2012 Jul 13;287(29):24460-72. doi: 10.1074/jbc.M112.382226. Epub 2012 May 30.
6
Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin.
J Biol Chem. 2012 Jun 29;287(27):22717-29. doi: 10.1074/jbc.M111.334565. Epub 2012 May 10.
7
8OHdG as a marker for Huntington disease progression.
Neurobiol Dis. 2012 Jun;46(3):625-34. doi: 10.1016/j.nbd.2012.02.012. Epub 2012 Mar 5.
8
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
Nat Med. 2011 Dec 18;18(1):153-8. doi: 10.1038/nm.2558.
9
Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway.
Nat Med. 2011 Dec 18;18(1):159-65. doi: 10.1038/nm.2559.
10
Early alterations of brain cellular energy homeostasis in Huntington disease models.
J Biol Chem. 2012 Jan 6;287(2):1361-70. doi: 10.1074/jbc.M111.309849. Epub 2011 Nov 28.
Zotero 插件